MIDAQ AB announces outcome of the written procedure regarding its senior unsecured bonds 2021/2024 with ISIN SE0017085319

The written procedure initiated through a notice on 23 May 2024 (the “Written Procedure”) regarding certain amendments to the terms and conditions for MIDAQ AB (publ)’s (the “Company”) outstanding bond loan 2021/2024 with ISIN SE0017085319 (the “Bonds”), has today been successfully completed.

The Written Procedure was initiated in order to request the bondholders’ consent to, extend the maturity date of the Bonds, amend the terms and conditions of the Bonds, and to waive an event of default under the terms and conditions of the Bonds, all as set out in the notice of Written Procedure, which is available on the Company’s website.

A sufficient number of bondholders participated in the Written Procedure to constitute a quorum, and a required majority of the bondholders voted in favour the Company’s request under the Written Procedure. Consequently, the agent, Nordic Trustee & Agency AB (publ), has today concluded the Written Procedure. The terms and conditions of the Bonds have been amended and restated effective from today, 12 June 2024, to reflect the approval of the request (the “Amended and Restated Terms and Conditions”). The Amended and Restated Terms and Conditions will be made available on the Company’s website.

Payment of the consent fee to the bondholders with respect to each Bond shall, pursuant to the notice of Written Procedure, be made within twenty (20) business days from the date of the expiration of the Written Procedure. Payment is expected to occur on 3 July 2024 (the “Payment Date”) to direct registered owners and registered authorised nominees of the Bonds in the Company’s debt ledger held with Euroclear Sweden as of the record date falling five (5) business days prior to the Payment Date.

Danske Bank A/S, Denmark, Sverige Filial acted as financial advisor and Advokatfirman Cederquist KB acted as legal advisor in connection with the Written Procedure.

For further information, please contact:

Stefan Engdahl, MD/CEO
Phone: +46 70 269 10 80
Email: stefan.engdahl@midaq.se

Håkan Sundberg, CFO
Phone: +46 70 269 10 81
Email: hakan.sundberg@midaq.se